| (AstraZeneca) D7630C00001 / TROPION-Breast05 | A Phase III, Open-label, Randomised Study of Datopotamab Deruxtecan (Dato-DXd) With or Without Durvalumab Compared with Investigator’s Choice of Chemotherapy (Paclitaxel, Nab-paclitaxel or Gemcitabine + Carboplatin) in Combination With Pembrolizumab in Patients with PD-L1 Positive Locally Recurrent Inoperable or Metastatic Triple-negative Breast Cancer (TROPION-Breast05) | Dr Louise Bordeleau | Open to recruitment | NCT06103864 |
| (CCTG) IND.241 - Master Protocol | A Liquid-biopsy Informed Platform Trial to Evaluate Treatment in CDK4/6-inhibitor Resistant ER+/HER2- Metastatic Breast Cancer | Dr Nidhi Kumar-Tyagi | Open to recruitment | NCT05601440 (Master) |
| (CCTG) MA.39 / TAILOR RT | A randomized trial of regional radiotherapy in Biomarker low risk node positive breast cancer (TAILOR RT) | Dr Timothy Whelan | Open to recruitment | NCT03488693 |
| OCOG-2021-ELISA | Prospective Evaluation of Breast-Conserving Surgery Alone in Low-Risk Ductal Carcinoma in Situ Defined by a Molecular Expression Assay Combined with Clinico-Pathological Features (ELISA Study) | Dr Timothy Whelan | Open to recruitment | NCT04797299 |
| OCOG-2022-RAPID2 | A Randomized Trial of Five-Fraction Partial Breast Irradiation (RAPID2) | Dr Do-hoon Kim | Open to recruitment | NCT05417516 |
Find a Trial
Contact Us